SCPX

PINK Scorpius Holdings, Inc.

Nov 11, 2026 · 6:41 AM ET EOD Market Closed

$0.0002 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0002, and at the day’s high of $0.0002

YTD change: +0.00%
vs 20-day SMA: -62.62%
vs 200-day SMA: -95.07%

Price ranges

Previous day

$0.0002 $0.0002

open $0.0002 close $0.0002

+$0.0000 (+0.00%)

Today

$0.0002 $0.0002

$0.0002

Past week

$0.0001 $0.0010

from $0.0001 now $0.0002

+$0.0001 (+100.00%)

Past month

$0.0001 $0.0015

from $0.0010 now $0.0002

-$0.0008 (-80.00%)

This year

$0.0001 $0.1000

from $0.0002 now $0.0002

+$0.0000 (+0.00%)

Price & Performance

-0.00 (-81.82%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 100.0% away from all-time highs of $7.2192
SCPX is up 0% since the beginning of the year
SCPX is down 83% over the past 12 months
SCPX is down 80% over the past 1 month
0% of all SCPX investors are betting against SCPX

SCPX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -83.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.0161

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Enterprise value $11.9M

Beta -21.89

Balance sheet & scale

IncomeN/A

Revenue$1.7M

Cash$600.8K

Debt$18.1K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $12.2K

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in San Antonio, TX.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,432.29	+1.44%
JNJ	Johnson & Johnson	$280.78	-0.47%
ABBV	AbbVie, Inc.	$293.89	+0.20%
MRK	Merck & Co., Inc.	$148.05	-0.48%
RHHVF	Roche Holding Ltd	$490.92	-0.31%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.